US biotech company Regeneron (Nasdaq: REGN) has provided an update on its coronavirus (COVID-19) antibody program.
The firm is seeking to discover and develop a multi-antibody cocktail that can be administered as prophylaxis before exposure to the SARS-CoV-2 virus, which causes the COVID-19 disease, or as treatment for those already infected.
Regeneron scientists have now isolated hundreds of virus-neutralizing, fully human antibodies from the company's VelocImmune mice, which have been genetically-modified to have a human immune system.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze